Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy
Erez N. Baruch, Frederico O. Gleber‐Netto, Priyadharsini Nagarajan, Xiayu Rao, Shamima Akhter, Tuany Eichwald, Tongxin Xie, Mohammad Balood, Adebayo Adewale, Shorook Na’ara, Hinduja Naidu Sathishkumar, Shajedul Islam, William Bernard McCarthy, Brandi J. Mattson, Renata Ferrarotto, Michael K. Wong, Michael A. Davies, Sonali Jindal, Sreyashi Basu, Karine Roversi, Amin Reza Nikpoor, Maryam Ahmadi, Ali Ahmadi, Catherine Harwood, Irene M. Leigh, Dennis Gong, Paulino Tallón de Lara, Derrick L. Tao, Tara M. Davidson, Nadim J. Ajami, P. Andrew Futreal, Kunal Rai, Veena Kochat, Micah Castillo, Preethi H. Gunaratne, Ryan P. Goepfert, Sharia Hernandez, Nikhil I. Khushalani, Jing Wang, Stephanie S. Watowich, George A. Călin, Michael R. Migden, Mona Yuan, Naijiang Liu, Yi Ye, William L. Hwang, Paola D. Vermeer, Nisha J. D’Silva, Yuri L. Bunimovich, Dan Yaniv, Jared K. Burks, Javier A. Gomez, Patrick M. Dougherty, Kenneth Y. Tsai, James P. Allison, Padmanee Sharma, Jennifer A. Wargo, Jeffrey N. Myers, Sébastien Talbot, Neil D. Gross, Moran Amit
Abstract
Perineural invasion (PNI) is a well-established factor of poor prognosis in multiple cancer types1, yet its mechanism remains unclear. Here we provide clinical and mechanistic insights into the role of PNI and cancer-induced nerve injury (CINI) in resistance to anti-PD-1 therapy. Our study demonstrates that PNI and CINI of tumour-associated nerves are associated with poor response to anti-PD-1 therapy among patients with cutaneous squamous cell carcinoma, melanoma and gastric cancer. Electron microscopy and electrical conduction analyses reveal that cancer cells degrade the nerve fibre myelin sheets. The injured neurons respond by autonomously initiating IL-6- and type I interferon-mediated inflammation to promote nerve healing and regeneration. As the tumour grows, the CINI burden increases, and its associated inflammation becomes chronic and skews the general immune tone within the tumour microenvironment into a suppressive and exhaustive state. The CINI-driven anti-PD-1 resistance can be reversed by targeting multiple steps in the CINI signalling process: denervating the tumour, conditional knockout of the transcription factor mediating the injury signal within neurons (Atf3), knockout of interferon-α receptor signalling (Ifnar1−/−) or by combining anti-PD-1 and anti-IL-6-receptor blockade. Our findings demonstrate the direct immunoregulatory roles of CINI and its therapeutic potential. Perineural invasion and cancer-induced nerve injury of tumour-associated nerves are associated with poor response to anti-PD-1 therapy, which can be reversed by combining anti-PD-1 therapy with anti-inflammatory interventions.